What is the address of DR.SYLVIE VERMEIRE NEFROLOGIE?

The registered office of DR.SYLVIE VERMEIRE NEFROLOGIE is located at Braambessendreef 8, 8020 Oostkamp.

Is DR.SYLVIE VERMEIRE NEFROLOGIE still active?

Yes. According to the CBE (17 September 2026) DR.SYLVIE VERMEIRE NEFROLOGIE is active, legal situation “Normale toestand”, started on 27 October 2010.

Is DR.SYLVIE VERMEIRE NEFROLOGIE registered on Peppol?

Yes, DR.SYLVIE VERMEIRE NEFROLOGIE is registered on the Peppol network with ID 0208:0830753332.

What is the enterprise number of DR.SYLVIE VERMEIRE NEFROLOGIE?

The enterprise number of DR.SYLVIE VERMEIRE NEFROLOGIE is BE0830753332.

When was DR.SYLVIE VERMEIRE NEFROLOGIE founded?

DR.SYLVIE VERMEIRE NEFROLOGIE was founded on 27 October 2010.

Who are the directors of DR.SYLVIE VERMEIRE NEFROLOGIE?

According to the 2025 annual accounts, the directors of DR.SYLVIE VERMEIRE NEFROLOGIE are: Sylvie Vermeire.

Is DR.SYLVIE VERMEIRE NEFROLOGIE a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 27 October 2010; 4 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did DR.SYLVIE VERMEIRE NEFROLOGIE make in 2025?

DR.SYLVIE VERMEIRE NEFROLOGIE posted a profit after taxes of € 341,697 in financial year 2025.

What is the revenue of DR.SYLVIE VERMEIRE NEFROLOGIE?

As a small company, DR.SYLVIE VERMEIRE NEFROLOGIE is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 460,075.

DR.SYLVIE VERMEIRE NEFROLOGIE (Private Limited)

Dossier DR.SYLVIE VERMEIRE NEFROLOGIE, printed on 17 September 2026 from databakkes.be/en/0830753332/dr-sylvie-vermeire-nefrologie. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

DR.SYLVIE VERMEIRE NEFROLOGIE from Oostkamp, company number BE0830753332, closed financial year 2025 with a result of € 341,697 after tax. For that financial year DR.SYLVIE VERMEIRE NEFROLOGIE recorded a gross margin of € 460,075 and equity of € 1.7 million. Compared with financial year 2024, the result moved from € 341,532 to € 341,697. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on March 9, 2026.

What it is worth Growing

€ 1.7 million

▲ 25% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 341,697

Profit after tax over the fiscal year.

Cash in the bank

€ 228,014

▲ 104% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 833 paid out

0 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Vehicles and equipment

€ 10,550

▼ 4% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt

€ 39,380

▲ 37% vs 2024

Loans from banks and other lenders, long and short.

Taxes

€ 40,107

▲ 4% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 352,254 Gross margin 2022: € 352,254 First fiscal year in the series	€ 452,181 Gross margin 2023: € 452,181 ▲ 28% vs 2022 (€ 352,254) Favourable step	€ 466,480 Gross margin 2024: € 466,480 ▲ 3% vs 2023 (€ 452,181) Favourable step	€ 460,075 Gross margin 2025: € 460,075 ▼ 1% vs 2024 (€ 466,480) Unfavourable step	▼ 1%
Profit after taxes	€ 254,830 Profit after taxes 2022: € 254,830 First fiscal year in the series	€ 325,262 Profit after taxes 2023: € 325,262 ▲ 28% vs 2022 (€ 254,830) Favourable step	€ 341,532 Profit after taxes 2024: € 341,532 ▲ 5% vs 2023 (€ 325,262) Favourable step	€ 341,697 Profit after taxes 2025: € 341,697 Unchanged (€ 341,532) Favourable step
Equity	€ 1,059,604 Equity 2022: € 1,059,604 First fiscal year in the series	€ 1,216,948 Equity 2023: € 1,216,948 ▲ 15% vs 2022 (€ 1,059,604) Favourable step	€ 1,366,402 Equity 2024: € 1,366,402 ▲ 12% vs 2023 (€ 1,216,948) Favourable step	€ 1,707,266 Equity 2025: € 1,707,266 ▲ 25% vs 2024 (€ 1,366,402) Favourable step	▲ 25%
Total debts	€ 254,699 Total debts 2022: € 254,699 First fiscal year in the series	€ 269,716 Total debts 2023: € 269,716 ▲ 6% vs 2022 (€ 254,699) Unfavourable step	€ 260,188 Total debts 2024: € 260,188 ▼ 4% vs 2023 (€ 269,716) Favourable step	€ 80,812 Total debts 2025: € 80,812 ▼ 69% vs 2024 (€ 260,188) Favourable step	▼ 69%
Cash	€ 310,490 Cash 2022: € 310,490 First fiscal year in the series	€ 169,576 Cash 2023: € 169,576 ▼ 45% vs 2022 (€ 310,490) Unfavourable step	€ 111,876 Cash 2024: € 111,876 ▼ 34% vs 2023 (€ 169,576) Unfavourable step	€ 228,014 Cash 2025: € 228,014 ▲ 104% vs 2024 (€ 111,876) Favourable step	▲ 104%
Land & buildings	-	-	-	€ 32,724 Land & buildings 2025: € 32,724 First fiscal year in the series
Retained profit	€ 1,047,204 Retained profit 2022: € 1,047,204 First fiscal year in the series	€ 1,204,548 Retained profit 2023: € 1,204,548 ▲ 15% vs 2022 (€ 1,047,204) Favourable step	€ 1,354,002 Retained profit 2024: € 1,354,002 ▲ 12% vs 2023 (€ 1,204,548) Favourable step	€ 1,694,866 Retained profit 2025: € 1,694,866 ▲ 25% vs 2024 (€ 1,354,002) Favourable step	▲ 25%
Dividend	€ 163,870 Dividend 2022: € 163,870 First fiscal year in the series	€ 167,918 Dividend 2023: € 167,918 ▲ 2% vs 2022 (€ 163,870) Unchanged	€ 192,078 Dividend 2024: € 192,078 ▲ 14% vs 2023 (€ 167,918) Unchanged	€ 833 Dividend 2025: € 833 ▼ € 191,245 vs 2024 (€ 192,078) Unchanged	▼ € 191,245
Bank debt	€ 40,917 Bank debt 2022: € 40,917 First fiscal year in the series	€ 0 Bank debt 2023: € 0 ▼ 100% vs 2022 (€ 40,917) Favourable step	€ 28,746 Bank debt 2024: € 28,746 Unchanged (€ 0) Unfavourable step	€ 39,380 Bank debt 2025: € 39,380 ▲ 37% vs 2024 (€ 28,746) Unfavourable step	▲ 37%
Balance sheet total	€ 1,314,303 Balance sheet total 2022: € 1,314,303 First fiscal year in the series	€ 1,486,663 Balance sheet total 2023: € 1,486,663 ▲ 13% vs 2022 (€ 1,314,303) Unchanged	€ 1,626,590 Balance sheet total 2024: € 1,626,590 ▲ 9% vs 2023 (€ 1,486,663) Unchanged	€ 1,788,078 Balance sheet total 2025: € 1,788,078 ▲ 10% vs 2024 (€ 1,626,590) Unchanged	▲ 10%

Key figures of DR.SYLVIE VERMEIRE NEFROLOGIE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 30 April 2027.

What happened to DR.SYLVIE VERMEIRE NEFROLOGIE?

What happened at DR.SYLVIE VERMEIRE NEFROLOGIE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Mar 9, 2026 New annual accounts for financial year 2025: profit of € 341,697. Source: NBB ↗
Oct 29, 2010 New establishment in Oostkamp. KBO
2010 Sylvie Vermeire became a director. NBB
Oct 27, 2010 Start of the company according to the CBE. KBO

In short

From € 254,830 profit in 2022 to € 341,697 profit in 2025.

Paid € 570,941 in corporate taxes since 2022.

Best year ever: 2025, with € 341,697 profit.

Paid out € 524,699 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at DR.SYLVIE VERMEIRE NEFROLOGIE? We notify you, reason included.

Follow DR.SYLVIE VERMEIRE NEFROLOGIE

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Sylvie Vermeire

DR.SYLVIE VERMEIRE NEFROLOGIE

Associatie Nefrologie AZ Sint-Lucas Assebroek BV 12.5%

Behind DR.SYLVIE VERMEIRE NEFROLOGIE is Sylvie Vermeire. It owns 12.5% of Associatie Nefrologie AZ Sint-Lucas Assebroek BV itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Sylvie Vermeire

Director

since 2010

Establishments

Establishment units

Physical locations of this company

Registered office

Braambessendreef 8

8020 Oostkamp

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.

All companies at this address →

Koninklijke Geneesheren van Brugge en het Noorden

DR.WOUTER DE KEYSER ORTHOPEDIE

€ 199,033 gross margin · 2025

Wosymmo

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0830.753.332
VAT number: BE 0830.753.332
Registered office: Braambessendreef 8, 8020 Oostkamp
Names & denominations: DR.SYLVIE VERMEIRE NEFROLOGIE
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 27 October 2010
Peppol: Active · Active since 5 Dec 2025
Contact: [email protected]

View on CBE Public ↗ Annual accounts (NBB) ↗